



[www.MedChemExpress.com](http://www.MedChemExpress.com)

Inhibitors, Screening Libraries, Proteins

# Pyk2

## Proline-rich tyrosine kinase 2

Proline-rich tyrosine kinase 2 (Pyk2) is a cytoplasmic, non-receptor tyrosine kinase implicated in multiple signaling pathways. It is a negative regulator of osteogenesis and considered a viable drug target for osteoporosis treatment.

Pyk2 and focal adhesion kinase (FAK) comprise the focal adhesion kinase subfamily of non-receptor tyrosine kinases. PYK2 and FAK are large multidomain proteins containing an N-terminal FERM domain, a central catalytic domain, and a C-terminal segment containing dual proline rich (PR) subdomains and a focal adhesion targeting (FAT) region.


Pyk2, a non-receptor tyrosine kinase of the FAK family, is up-regulated in more than 60% of the tumors of hepatocellular carcinoma (HCC) patients.

## Pyk2 Inhibitors

### NVP-TAE 226 (TAE226)

Cat. No.: HY-13203

NVP-TAE 226 (TAE226) is a potent and ATP-competitive dual **FAK** and **IGF-1R** inhibitor with  $IC_{50}$ s of 5.5 nM and 140 nM, respectively. NVP-TAE 226 (TAE226) also effectively inhibits **Pyk2** and **insulin receptor (InsR)** with  $IC_{50}$ s of 3.5 nM and 44 nM, respectively.




**Purity:** 99.92%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

### PF-431396

Cat. No.: HY-10460

PF-431396 is an orally active dual **focal adhesion kinase (FAK)** and **proline-rich tyrosine kinase 2 (PYK2)** inhibitor, with  $IC_{50}$  values of 2 nM and 11 nM, respectively.




**Purity:** 98.86%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

### PF-4618433

Cat. No.: HY-18312

PF-4618433 is a potent and selective **PYK2** inhibitor, with an  $IC_{50}$  of 637 nM. PF-4618433 may be suitable for the research of osteoporosis, craniofacial and appendicular skeletal defects and for targeted bone regeneration.




**Purity:** 98.41%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

### PF-562271

(VS-6062)

Cat. No.: HY-10459

PF-562271 (VS-6062) is a potent, ATP-competitive and reversible **FAK** and **Pyk2** kinase inhibitor with  $IC_{50}$ s of 1.5 nM and 13 nM, respectively.




**Purity:** 99.68%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

### PF-562271 besylate

(VS-6062 besylate)

Cat. No.: HY-10458

PF-562271 (VS-6062) besylate is a potent ATP-competitive, reversible inhibitor of **FAK** and **Pyk2** kinase, with an  $IC_{50}$  of 1.5 nM and 13 nM, respectively.




**Purity:** 99.17%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

### PF-562271 hydrochloride

(VS-6062(hydrochloride))

Cat. No.: HY-20403

PF-562271 (VS-6062) hydrochloride is a potent, ATP-competitive and reversible **FAK** and **Pyk2** kinase inhibitor with  $IC_{50}$ s of 1.5 nM and 13 nM, respectively.



**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg